文献速递产科母胎医学

围存活期双胎妊娠22至25周产前皮质类固醇给药:一项基于全国的研究

Antenatal corticosteroid administration in periviable twin pregnancies between 22 and 25 weeks: a nationwide-based study.
PubMed 文献 · Am J Obstet Gynecol · 2025-11-15

该横断面研究利用美国国家卫生统计中心2016-2022年出生数据,纳入15833例22-26周双胎分娩,其中44%暴露于产前皮质类固醇。暴露组新生儿存活率在22-23周、23-24周、24-26周均高于未暴露组,10分钟Apgar评分<7的 odds 更低;2016至2022年皮质类固醇使用率显著上升,22周尤其明显。

要点

  • 22-23周双胎暴露于产前皮质类固醇者存活率55.9% vs 未暴露26.8%(aOR 3.66)。
  • 23-24周存活率74.1% vs 65.6%(aOR 1.53),24-26周85.4% vs 82.2%(aOR 1.21)。
  • 仅限接受积极产后干预的新生儿,22周和23周存活获益仍显著(aOR 2.5和1.56)。

核心结论

  • 围存活期双胎产前皮质类固醇给药与新生儿存活改善相关,尤其在22和23周,并与短期不良结局 odds 降低相关。
  • 在接受积极产后干预的新生儿中存活获益持续存在,提示计划 intensive 新生儿 care 时产前皮质类固醇有益。
  • 这些发现仅限于短期新生儿结局,应在现有数据的限制内解读。

研究设计与样本

  • 横断面研究,使用美国国家卫生统计中心与疾病控制与预防中心2016-2022年出生数据集。
  • 纳入22至26周分娩的双胎妊娠,排除单胎、高阶多胎、该孕周窗口外分娩及产前皮质类固醇数据缺失者。
  • 共纳入15833例双胎分娩,其中6982例(44%)暴露于产前皮质类固醇,8851例(56%)未暴露。

主要发现

  • 22-23周存活率暴露组55.9% vs 未暴露组26.8%(aOR 3.66,95%CI 2.95-4.55)。
  • 23-24周存活率暴露组74.1% vs 未暴露组65.6%(aOR 1.53,95%CI 1.30-1.79);24-26周85.4% vs 82.2%(aOR 1.21,95%CI 1.02-1.44)。
  • 10分钟Apgar评分<7的 odds 在22-23周暴露组53.0% vs 未暴露组66.8%(aOR 0.56,95%CI 0.45-0.69);23-24周30.6% vs 36.5%(aOR 0.84,95%CI 0.72-0.98);24-26周17.4% vs 23.2%(aOR 0.68,95%CI 0.58-0.80)。
  • 仅限接受积极产后干预的新生儿(n=9118),存活获益在22周(aOR 2.5,95%CI 1.77-3.54)和23周(aOR 1.56,95%CI 1.26-1.94)仍显著。
  • 2016至2022年产前皮质类固醇使用率在所有孕周显著增加,22周从13.5%升至42.9%(P<.0001);2020年26.1%至2022年42.9%(P<.0001)。

临床怎么用

  • 原文结论指出,计划 intensive 新生儿 care 时产前皮质类固醇使用可带来获益,但 findings 限于短期新生儿结局。

局限性

  • 原文结论写明这些发现仅限于短期新生儿结局,并应在现有数据的限制内解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Twin pregnancies are markedly increased risk of preterm birth, with a growing proportion delivering at periviable gestational ages. While antenatal corticosteroid administration improves neonatal outcomes in singleton pregnancies, evidence specific to twins at the threshold of viability remains limited. OBJECTIVE: To evaluate trends in antenatal corticosteroid administration and compare neonatal outcomes between antenatal corticosteroid-exposed and unexposed twin pregnancies delivered between 22 and 26 weeks' gestation. STUDY DESIGN: A cross-sectional study using the National Center for Health Statistics and Centers for Disease Control and Prevention natality dataset (2016-2022). Twin pregnancies delivered between 22 and 26 weeks' gestation were included. Singletons, higher-order multiples, neonates delivering outside of this gestational age window, and those missing antenatal corticosteroid data were excluded. The primary outcome was neonatal survival; secondary outcomes included 10-minute Apgar score <7, prolonged ventilation, surfactant therapy, suspected neonatal sepsis, and composite adverse outcomes defined as ventilation, 10-minute Apgar score <7, or death. Adjusted odds ratios were estimated using multivariable logistic regression. RESULTS: Among 15,833 twin births at 22 to 26 weeks, 6982 (44%) were exposed to antenatal corticosteroid, while 8851 (56%) were unexposed. Antenatal corticosteroid administration was linked to higher neonatal survival at 22 to 23 weeks (55.9% vs 26.8%; adjusted odds ratio, 3.66; 95% confidence interval, 2.95-4.55), 23 to 24 weeks (74.1% vs 65.6%; adjusted odds ratio, 1.53; 95% confidence interval, 1.30-1.79), and 24 to 26 weeks (85.4% vs 82.2%; adjusted odds ratio, 1.21; 95% confidence interval, 1.02-1.44). The odds of a 10-minute Apgar score <7 were lower with antenatal corticosteroid at 22 to 23 weeks (53.0% vs 66.8%; adjusted odds ratio, 0.56; 95% confidence interval, 0.45-0.69), 23 to 24 weeks (30.6% vs 36.5%; adjusted odds ratio, 0.84; 95% confidence interval, 0.72-0.98), and 24 to 26 weeks (17.4% vs 23.2%; adjusted odds ratio, 0.68; 95% confidence interval, 0.58-0.80). When the analysis was limited to neonates who received active postnatal intervention (n=9118), the survival benefit of antenatal corticosteroid remained significant at both 22 weeks (adjusted odds ratio, 2.5; 95% confidence interval, 1.77-3.54) and 23 weeks (adjusted odds ratio, 1.56; 95% confidence interval, 1.26-1.94). Between 2016 and 2022, antenatal corticosteroid utilization increased significantly across all gestational ages, particularly at 22 weeks' gestation, where antenatal corticosteroid use rose from 13.5% to 42.9%, a more than 3-fold increase (P<.0001). This upward trend in antenatal corticosteroid use was statistically significant when comparing the periods before and after the release of the American College of Obstetricians and Gynecologists advisory in 2021 on periviable corticosteroid administration, most pronounced at 22 weeks, with a rise from 26.1% in 2020 to 42.9% in 2022 (P<.0001). CONCLUSION: Antenatal corticosteroid administration in twin pregnancies at periviable gestational ages is associated with improved neonatal survival, especially at 22 and 23 weeks, and with lower odds of short-term neonatal adverse outcomes. The survival benefit persists among neonates receiving active postnatal intervention, suggesting that antenatal corticosteroid use confers benefit when intensive neonatal care is planned. However, these findings are limited to short-term neonatal outcomes and should be interpreted within the constraints of the available data.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Mustafa HJ, Aghajani F, Lenchner E, et al. Antenatal corticosteroid administration in periviable twin pregnancies between 22 and 25 weeks: a nationwide-based study. Am J Obstet Gynecol. 2025. PMID: 41248783. doi:10.1016/j.ajog.2025.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。